Clinical trials: Abiraterone ACetate
Prostatic Neoplasms
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under…
- Trial name
- NCT04577833
- Testing
- Niraparib, Abiraterone Acetate (AA), Prednisone
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03279250
- Testing
- Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with…
- Trial name
- eRADicAte (NCT02097303)
- Testing
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Carolina Research Professionals, LLC
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01848067
- Testing
- Alisertib, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Salivary Glands Tumors
Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Carcinomas of the salivary glands (SGCs) are rare tumors. Some selected salivary gland histotypes such as salivary duct carcinomas (SDC) and adenocarcinomas, NOS (not otherwise specified) distinguish themselves for the expression…
- Trial name
- SG-ABI14 (NCT02867852)
- Testing
- Abiraterone acetate
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Prostate Cancer
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of…
- Trial name
- NCT01485861
- Testing
- Abiraterone, Apitolisib, Ipatasertib
- Where
- 59 sites in United States, Czechia and 7 more
- Volunteers
- 298 people
- Sponsor
- Genentech, Inc.
Prostate Neoplasms
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with advanced metastatic castration resistant prostate cancer (CRPC) who have received prior chemotherapy…
- Trial name
- NCT01692483
- Testing
- Abiraterone acetate, Prednisone
- Sponsor
- Janssen Pharmaceutica
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s).
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- HARMONY (NCT06392841)
- Testing
- Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate
- Sponsor
- Qian Qin
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in…
- Trial name
- NCT01381874
- Testing
- Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
- Where
- 81 sites in United States, Belgium and 10 more
- Volunteers
- 297 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
- Trial name
- NCT01591122
- Testing
- Abiraterone acetate and prednisone
- Where
- 22 sites in China, Malaysia and 2 more
- Volunteers
- 313 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
The purpose of this research study is to test the safety and possible side effects of Lutetium-177 (177Lu)-Prostate-Specific Membrane Antigen (PSMA)-617 along with niraparib and abiraterone acetate plus prednisone when it is…
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- LUNAAR (NCT06329830)
- Testing
- 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone
- Where
- United States
- Sponsor
- Baptist Health South Florida
Metastatic Castration Resistant Prostate Cancer
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of ketoconazole.
- Trial name
- NCT04056754
- Testing
- Abiraterone Acetate, Prednisone
- Where
- 16 sites in China
- Volunteers
- 268 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Neoplasms
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
- Trial name
- NCT00473746
- Testing
- Abiraterone acetate, prednisone/prednisolone or dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after…
- Trial name
- REAAcT (NCT02663193)
- Testing
- No Intervention
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Scientific Affairs, LLC
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Neoplasms, Prostate Cancer
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic…
- Trial name
- NCT01424930
- Testing
- Abiraterone, Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Janssen-Ortho Inc., Canada
Prostate Cancer
Abiraterone Acetate for Castrate Resistant Prostate Cancer
This research study is a Pilot clinical trial. Pilot clinical trials often examine new tests (such as laboratory or radiology tests) in patients who receive either standard cancer treatments or new treatments that have been…
- Trial name
- NCT01961843
- Testing
- Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
21-hydroxylase Deficiency
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase…
- Trial name
- NCT01495910
- Testing
- Abiraterone acetate
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prostate Cancer
SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone
Abiraterone acetate (AA) has shown a favourable impact in overall survival, administered with prednisone to decrease the adverse event related to CYP171A suppression.
- Trial name
- NCT02928432
- Testing
- Steroids switch
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III